Cannabidiol Supplements in Romania: Market Claims vs. Clinical Evidence
Author Information
Author(s): Andrei Corina, Nitulescu George Mihai, Nitulescu Georgiana, Zanfirescu Anca
Primary Institution: Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Hypothesis
This study investigates the inconsistencies between the health claims associated with cannabidiol (CBD) supplements and the evidence from clinical trials.
Conclusion
The study found significant discrepancies between marketed claims of CBD supplements and the clinical evidence supporting their efficacy.
Supporting Evidence
- Some claims about CBD's effectiveness for conditions like PTSD lack substantial clinical evidence.
- Recommended dosages for marketed CBD supplements are often lower than those used in clinical trials.
- Stricter regulatory oversight is needed to align consumer expectations with scientific evidence.
Takeaway
This study looked at CBD products sold in Romania and found that many claims about their benefits are not backed by solid scientific evidence.
Methodology
A systematic review of online pharmacies and clinical trials was conducted to assess the efficacy of CBD products available in Romania.
Potential Biases
Potential bias in product claims due to lack of regulatory oversight.
Limitations
The study primarily focused on marketed products and may not represent all CBD products available.
Participant Demographics
Products were selected from online pharmacies in Romania, with no specific demographic data on consumers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website